Skip to main content
. Author manuscript; available in PMC: 2020 Mar 15.
Published in final edited form as: Int J Radiat Oncol Biol Phys. 2018 Nov 27;103(4):878–886. doi: 10.1016/j.ijrobp.2018.11.008

Table 2.

Joint Radiation/Chemotherapy Review

All Patients Patients starting
Irinotecan
Patients not starting Irinotecan
(n=152) (n=95) (n=57)
Chemo Review Chemo Review Chemo Review
Per
Protocol
Not Per
Protocol
Not
Evaluable
Per
Protocol
Not Per
Protocol
Not
Evaluable
Per
Protocol
Not Per
Protocol
Not
Evaluable
n % n % n % n % n % n % n % n % n %
Per protocol 83 54 50 33 2 1 61 64 31 33 1 1 22 39 19 33 1 2
Acceptable variation 7 5 3 2 0 0 2 2 0 0 0 0 5 9 3 5 0 0
Unacceptable deviation 1 1 1 1 0 0 0 0 0 0 0 0 1 2 1 2 0 0
Incomplete RT (death during RT) 0 0 1 1 0 0 0 0 0 0 0 0 0 0 1 2 0 0
Incomplete RT (progression) 3 2 0 0 0 0 0 0 0 0 0 0 3 5 0 0 0 0
Incomplete RT (refusal) 0 0 1 1 0 0 0 0 0 0 0 0 0 0 1 2 0 0